The FDA on Monday granted marketing approval for Bystolic, a blood pressure drug developed by Mylan and Forest Laboratories. Forest Labs will be responsible for marketing the drug, also known as nebivolol, while Mylan will receive a share of the royalties and an option to join future co-promotions.

Full Story:
Reuters, Bloomberg

Related Summaries